The Short Answer
Ozempic is FDA-approved with a well-characterized safety profile. Like all medications, it carries risks—but for appropriate patients, the benefits of treating type 2 diabetes (or obesity with Wegovy) substantially outweigh those risks. The key is proper patient selection and ongoing monitoring.
Ozempic (semaglutide) is FDA-approved for type 2 diabetes, not weight loss. For weight management, the same molecule is available as Wegovy, which is FDA-approved for chronic weight management. At PEAK, we prescribe Wegovy for weight-loss patients.
What Clinical Trials Showed
Ozempic’s safety was established through the SUSTAIN clinical trial program—a series of randomized, controlled studies in patients with type 2 diabetes. The weight management version, Wegovy, was studied in the STEP program. Together, these trials enrolled over 16,000 participants.
Common Side Effects (Occurring in >5% of Patients)
| Side Effect | Semaglutide | Placebo | Resolves? |
|---|---|---|---|
| Nausea | 20–44% | 6–16% | Usually within 4–8 weeks |
| Diarrhea | 8–30% | 6–16% | Often resolves with diet adjustment |
| Vomiting | 5–24% | 2–11% | Typically during dose escalation |
| Constipation | 5–24% | 4–11% | Manageable with fiber and hydration |
| Abdominal pain | 5–20% | 4–12% | Usually mild and transient |
| Headache | 5–14% | 4–13% | Typically resolves |
The most notable pattern: GI side effects are dose-dependent, most pronounced during titration, and resolve for the majority of patients. Fewer than 5–7% of trial participants discontinued due to side effects.
Discontinuation Rates
In the STEP 1 trial (Wegovy 2.4 mg for weight management), 7% of semaglutide patients discontinued due to adverse events vs. 3.1% on placebo. For the diabetes-dose SUSTAIN trials, discontinuation rates were even lower. These rates compare favorably to many chronic medications.
The Boxed Warning: Thyroid C-Cell Tumors
Ozempic carries a boxed warning (the most serious FDA warning category) regarding thyroid C-cell tumors:
- In rodent studies, semaglutide caused thyroid C-cell tumors (medullary thyroid carcinoma) at clinically relevant doses
- It is unknown whether semaglutide causes thyroid C-cell tumors in humans
- The relevance to humans is uncertain because rodents have significantly more GLP-1 receptors in the thyroid than humans
- Long-term human data (now over 8 years with GLP-1 medications broadly) has not shown increased medullary thyroid carcinoma rates
The boxed warning exists out of appropriate caution, not because a clear human risk has been demonstrated. After millions of patient-years of GLP-1 receptor agonist use, population-level data has not confirmed the thyroid cancer risk seen in rodents.
Contraindication: Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Serious but Rare Risks
Pancreatitis
Acute pancreatitis has been reported in patients taking GLP-1 receptor agonists, including semaglutide. The incidence is low (less than 1% in clinical trials), and a direct causal relationship hasn’t been definitively established. However:
- Patients should report severe, persistent abdominal pain immediately
- Semaglutide should be discontinued if pancreatitis is suspected
- Patients with a history of pancreatitis should be monitored closely
Gallbladder Disease
Rapid weight loss (from any cause) increases the risk of gallstones and cholecystitis. In the STEP trials, cholelithiasis occurred in approximately 1.6% of semaglutide patients vs. 0.7% on placebo. This is a risk of rapid weight loss generally, not unique to semaglutide.
Acute Kidney Injury
Reported rarely, usually in the context of severe dehydration from vomiting or diarrhea. Maintaining adequate hydration and reporting persistent GI symptoms prevents most cases.
Diabetic Retinopathy Complications
In the SUSTAIN-6 trial, rapid blood sugar improvement was associated with worsening diabetic retinopathy in some patients with existing eye disease. This is thought to be related to the speed of glycemic improvement rather than semaglutide itself. Patients with known diabetic retinopathy should be monitored by an ophthalmologist.
Hypoglycemia
Semaglutide alone has a low risk of hypoglycemia because it stimulates insulin secretion in a glucose-dependent manner. However, when combined with insulin or sulfonylureas, the hypoglycemia risk increases and dose adjustments of those medications may be needed.
Who Should Not Take Ozempic
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome
- History of serious allergic reaction to semaglutide or any component of the medication
- Pregnant or planning to become pregnant (stop 2+ months before conception)
- History of pancreatitis (use with caution; some providers avoid entirely)
- Severe gastroparesis (semaglutide further slows gastric emptying)
- Active gallbladder disease (weight loss may worsen symptoms)
Your provider will review your complete medical history to determine whether semaglutide is appropriate for your specific situation.
Long-Term Safety Data
One of the most reassuring developments for semaglutide safety is the SELECT trial—a cardiovascular outcomes study that followed over 17,600 patients for a median of 3.3 years:
- 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death)
- No new safety signals emerged during extended follow-up
- The cardiovascular benefit was consistent across subgroups
- This trial led to Wegovy receiving an expanded FDA indication for cardiovascular risk reduction
The SELECT data provides the strongest long-term safety evidence for any GLP-1 medication—not only confirming absence of unexpected risks but demonstrating cardiovascular protective effects.
Weighing Benefits Against Risks
For patients with type 2 diabetes or obesity, the risks of not treating typically far exceed the medication’s risks:
| Untreated Obesity/Diabetes Risk | Semaglutide Risk |
|---|---|
| Heart disease (leading cause of death) | 20% cardiovascular risk reduction |
| Stroke | Reduced stroke risk demonstrated |
| Type 2 diabetes progression | Improved glycemic control |
| Sleep apnea | Significant improvement with weight loss |
| Joint disease | Reduced joint stress from weight loss |
| Reduced life expectancy (5–20 years) | GI side effects (usually temporary and manageable) |
This doesn’t minimize semaglutide’s real risks—they exist and deserve monitoring. But appropriate perspective matters: untreated obesity is among the most dangerous chronic conditions, and effective treatment dramatically changes outcomes.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
